BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 55 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2020. The put-call ratio across all filers is 0.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20 | -90.3% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $206 | -37.6% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $330 | +101.2% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $164 | – | 100 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2021 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2020 | $0 | -100.0% | 100 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $2,000 | +100.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $1,000 | – | 100 | 0.0% | 0.00% | – |
| Q1 2020 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | – | 100 | 0.0% | 0.00% | – |
| Q3 2018 | $0 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ABNER HERRMAN & BROCK LLC | 239,000 | $2,679,000 | 0.48% |
| EAM Investors, LLC | 81,854 | $918,000 | 0.20% |
| CFO4Life Group, LLC | 12,003 | $135,000 | 0.05% |
| Phoenix Holdings Ltd. | 104,782 | $1,112,000 | 0.05% |
| WINTON GROUP Ltd | 118,487 | $1,328,000 | 0.03% |
| Merit Financial Group, LLC | 28,731 | $322,000 | 0.03% |
| HighPoint Advisor Group LLC | 13,533 | $151,000 | 0.03% |
| SHANDA ASSET MANAGEMENT HOLDINGS Ltd | 23,000 | $258,000 | 0.02% |
| ETF MANAGERS GROUP, LLC | 52,216 | $579,000 | 0.02% |
| IHT Wealth Management, LLC | 13,000 | $146,000 | 0.02% |